News Release

Source of pregnancy complications from infections revealed by placenta map

Peer-Reviewed Publication

Wellcome Trust Sanger Institute

The first panoramic view of infection pathways in the human placenta has been created, which could highlight potential drug targets to develop pregnancy-safe therapies for malaria, toxoplasmosis and listeria, all diseases that can cause severe pregnancy complications.    

Researchers from the Wellcome Sanger Institute, the University of Cambridge, the University of Dundee, and collaborators, used novel ‘mini placenta’ models to map the placental response to infections in early development. This work is part of the wider Human Cell Atlas consortium1, which aims to map every cell type in the human body to transform our understanding of health and disease.

The study, published today (3 May) in Cell Systems, focused on the pathways involved in malaria, toxoplasmosis, and listeria infection, all of which can cause pregnancy complications and miscarriage. It revealed that secondary inflammation may be the cause of pregnancy complications during these infections and uncovered that placental immune cells are likely to play a defensive role against pathogens.

Future work focusing on identifying potential drug targets in the pathways that cause complications during infection could inform the design of more directed therapies to tackle infections in early-stage pregnancies.

Infections during pregnancy are a major global health concern2 affecting millions of people around the world. These infections can potentially cause maternal death, sepsis, and pregnancy complications, including miscarriage, foetal developmental conditions, low birth weight, and stillbirth3.

Malaria, toxoplasmosis, and listeria are widespread infections that can lead to pregnancy complications. This is of particular concern in regions where these infections are more common.  For example, in Sub-Saharan Africa and parts of Southeast Asia where the malaria parasite Plasmodium falciparum is endemic4.

The placenta acts as a selective barrier during pregnancy, which allows nutrients to cross from mother to baby while blocking pathogens and toxins.

However, the pathogens that cause toxoplasmosis and listeria can cross the placenta, and the parasite responsible for malaria can attach to the outside. The foetus is particularly vulnerable during early-stage development as the immune response is not fully established, meaning that the foetus relies heavily on the placental barrier for protection.

Despite the impact of infections during pregnancy, the pathways and mechanisms these infections use to cross the placenta are poorly understood, partly due to the limitations of laboratory models used and differences between humans and mice.

In the latest study from the Wellcome Sanger Institute and collaborators, the team established ex vivo explant models, or ‘mini placentas’ from human samples5, which allowed them to map the response to infection at single-cell resolution.  

The researchers identified a type of foetal immune cell, known as a Hofbauer cell, that were activated in all three types of infection but in different pathways. This is the first time that placental immune cells have been shown to play a defensive role against pathogens in a model of the human placenta.  

The team found that pathogens can infiltrate these immune cells. For example, T. gondii, the parasite that causes toxoplasmosis, is likely to use these immune cells to evade the ongoing immune response and travel around the body.

They also discovered that all three infections induced a general inflammatory response in the placenta which dysregulated placental functions. This suggests that secondary inflammation may be the cause of some pregnancy complications.

Targeting these inflammation pathways could lead to pregnancy-specific treatment for infections, which is not currently possible.

In addition to this, the ‘mini placenta’ models developed by this team can be used in future research to gain more insights into placental response to infections as well as wider placental changes during development. 

Dr Regina Hoo, co-first author from the Wellcome Sanger Institute, said: “While infections during pregnancy have been known to cause complications, including miscarriage and stillbirth, very little has been known about the underlying mechanisms. Our research shows that even with pathogens that cannot cross the placenta, the secondary inflammation from the immune system may be responsible for disrupting foetal development. Identifying key processes involved with the inflammation pathway could help us develop pregnancy-specific treatments that minimise this in the future.”

Elias Ruiz-Morales, co-first author from the Wellcome Sanger Institute, said: “We discovered that placental immune cells called macrophages can protect the placenta against infections. This is the first time that placental immune cells have been shown to play a defensive role in early-stage pregnancy in humans, and that these immune cells can be hijacked by toxoplasma during infection. Understanding more about how the placental immune system works can help give new insights into pregnancy complications.”  

Dr Marcus Lee, co-senior author from the Wellcome Sanger Institute, now at the University of Dundee, said: “Millions of pregnancies each year are potentially exposed to malaria, and understanding how the parasite adapts during infection and how the body responds will be important in improving outcomes. However, studying the interactions between pathogens and the human placenta is understandably incredibly difficult and therefore the development of new models, such as the placental tissue system we used in this research, are a much-needed step forward.”

Dr Roser Vento-Tormo, co-senior author from the Wellcome Sanger Institute, said: “Infections during pregnancy can have devastating impacts, and there are limited pregnancy-specific treatment options that can help. By mapping the pathways involved in infection during early-stage pregnancy in single-cell resolution, and developing new placental models to study this, we hope that our research can be used by the research community worldwide to help develop new ways to understand and treat pregnancy complications that impact millions of lives every year.” 



Contact details:
Rachael Smith

Press Office
Wellcome Sanger Institute
Cambridge, CB10 1SA


Notes to Editors:

  1. The Human Cell Atlas (HCA) consortium aims to map every cell type in the human body as a basis for both understanding human health and for diagnosing, monitoring, and treating disease. An open, scientist-led consortium, HCA is a collaborative effort of researchers, institutes, and funders worldwide, with more than 3,400 members from 101 countries across the globe.
  2. A, Seale. (2020) Recognising the burden of maternal infection worldwide. The Lancet. DOI:
  3. Chan MY, Smith MA. (2018) Infections in Pregnancy. Comprehensive Toxicology. Epub. DOI: 10.1016/B978-0-12-801238-3.64293-9.
  4. World Health Organization, World Malaria Report 2023. Available at
  5. All tissue samples were obtained with written informed consent from all participants in accordance with ethics guidelines and regulations.


R. Hoo, E. R. Ruiz-Morales, I. Kelava, et al. (2024) Acute response to pathogens in the early human placenta at single cell resolution. Cell Systems. DOI: 10.1016/j.cels.2024.04.002


This research was funded by Wellcome and UKRI. Full details can be found on the publication.

Selected websites:

University of Dundee School of Life Sciences:


  • The UK's Number 1 University for biological sciences (2014 and 2021 Research Excellence Framework), with scientists translating basic and clinical research to address global health challenges
  • One of the leading universities in the UK for spinning out and commercialising research, creating companies such as Exscientia and Amphista Therapeutics.
  • Our research-led teaching is preparing the next-generation of employable graduates with degrees that have a real-world focus.

University of Cambridge

The University of Cambridge is one of the world’s top ten leading universities, with a rich history of radical thinking dating back to 1209. Its mission is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence.

The University comprises 31 autonomous Colleges and 150 departments, faculties and institutions. Its 24,450 student body includes more than 9,000 international students from 147 countries. In 2020, 70.6% of its new undergraduate students were from state schools and 21.6% from economically disadvantaged areas.

Cambridge research spans almost every discipline, from science, technology, engineering and medicine through to the arts, humanities and social sciences, with multi-disciplinary teams working to address major global challenges. Its researchers provide academic leadership, develop strategic partnerships and collaborate with colleagues worldwide.

The University sits at the heart of the ‘Cambridge cluster’, in which more than 5,300 knowledge-intensive firms employ more than 67,000 people and generate £18 billion in turnover. Cambridge has the highest number of patent applications per 100,000 residents in the UK.

The Wellcome Sanger Institute

The Wellcome Sanger Institute is a world leader in genomics research. We apply and explore genomic technologies at scale to advance understanding of biology and improve health. Making discoveries not easily made elsewhere, our research delivers insights across health, disease, evolution and pathogen biology. We are open and collaborative; our data, results, tools, technologies and training are freely shared across the globe to advance science.

Funded by Wellcome, we have the freedom to think long-term and push the boundaries of genomics. We take on the challenges of applying our research to the real world, where we aim to bring benefit to people and society.

Find out more at or follow us on Twitter, Instagram, FacebookLinkedIn and on our Blog.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.